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Abstract  
Foot-and-mouth disease virus (FMDV) gives rise to a highly contagious and 
economically important disease of cloven-hooved animals. Vaccination reduces the 
economic impact by inducing serotype-specific protection. Recently, a replication-
defective adenovirus-vectored foot-and-mouth disease (FMD) subunit vaccine was 
developed and licensed. Serum virus neutralization (SVN) titer ≥1.5 to FMDV is the best 
predictor of vaccine-induced protection. However, protection does not always correlate 
with the presence of neutralizing antibodies. For example, some animals with high SVN 
titer develop signs of disease, and conversely, some animals with negligible SVN titer are 
protected. Categorizing cattle on the parameters of seroconversion and protection status 
yields four groups of cattle. Two of these groups are the expected outcome, protected 
with SVN titer ≥1.2 and unprotected with SVN titer <1.2. The other two groups are the 
rare but unexpected outcome, unprotected with SVN titer ≥1.2 and protected with SVN 
titer <1.2. The current study examines these rare but unexpected outcomes. Studying 
these unexpected outcomes may enhance our understanding of vaccine-induced 
protection in cattle administered the replication-defective Ad-5 vectored FMDV subunit 
vaccine (Ad-5 FMDV). Additionally, an alternative indicator of protection may provide 
additional clues as to the mechanism of immune protection that affords protection in 
animals with low SVN titers, and ultimately may lead to improvements in vaccine design. 
I hypothesized that gene expression analysis of bovine peripheral blood cells would 
provide a genomic tool for predicting Ad5-FMDV vaccine efficacy for foot-and-mouth 
disease. Thus, I sought to identify genes associated with protection after vaccination with 
Ad-5 FMDV. 
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Microarray-based analysis of mRNA transcripts from peripheral blood leukocytes of 
vaccinated cattle (n=21), drawn on 0, 1, 14 and 15 days post-vaccination, revealed that in 
response to Ad-5 FMDV, protected cattle (n=5) demonstrated a rapid but short-lived 
induction of stress-related genes. Vaccination with the adenovirus vaccine vector alone, 
ad-null, (n=4) resulted in a similar, but less robust, expression pattern, whereas 
unprotected cattle (n=4) exhibited an initially mild, but increasing expression profile of 
stress-related genes. A subset of 12 immune response-related genes was verified by RT-
qPCR. A separate list of genes that correlated with protection was identified. One gene in 
particular, CCL8, an inflammatory mediator, resulted in a transient up-regulation that was 
associated with protection, whereas vaccinated, but unprotected animals, exhibited a 
pattern of prolonged expression that did not return to baseline levels. Rapid but transient 
induction of the CCL8 gene in Ad5-FMDV vaccinated cattle correlated with protection, 
irrespective of SVN titer. These microarray-based results were verified with RT-qPCR 
using a TaqMan™ probe. Capture ELISA was unable to detect the CCL8 protein in 
plasma. This small study was expanded to a larger cohort of cattle (n=39) utilizing RT-
qPCR. From the 32 protected cattle in this expanded study, I was unable to conclude that 
transient up-regulation of CCL8 mRNA following vaccination correlated with protection. 
Thus, although CCL8 transient up-regulation could not be confirmed as a sole correlate 
of immune protection, it may be possible that transient up-regulation of CCL8 mRNA 
contributes to protection with other mechanistic immune functions that supplement or co-
correlate with protection. Perhaps transient up-regulation of CCL8 is one of multiple 
biomarkers that contribute to protection. Once the biological underpinnings of protection 
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are better understood perhaps these complex correlates of vaccine-induced protection will 
be readily identified.  
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Introduction 
 
Foot-and-Mouth Disease  
 
Foot-and-mouth disease (FMD) is highly contagious and economically 
devastating, affecting wild and domestic cloven-hoofed animal species [1]. The acute 
viral-borne disease is characterized by vesicular lesions on the tongue, snout, buccal 
cavity, feet and teats [2]. The incubation period in individual animals is highly variable 
ranging from 1-14 days and is dependent on the strain and dose of virus, the route of 
transmission, the animal species and the husbandry conditions [3]. FMD generally 
resolves within 7-10 days without treatment. Adult convalescent animals may serve as 
carriers of FMDV and potentially initiate new outbreaks [4-7]. Carrier animals for FMD 
are animals, which have a persistent unobvious infection, from which it is possible to 
isolate infectious FMDV intermittently 28 days or more after infection. Fatal cases are 
rare in adult animals but may occur in young animals due to myocarditis [8]. Thus, the 
morbidity, high transmissibility, wide dissemination and significant economic impact 
makes FMD among the most feared livestock diseases and a major research focus for 
more than a century.  
FMD is the first disease for which the world organization for animal health (OIE) 
(formerly known as the Office International des Epizooties) established an official list of 
FMDV-free countries and zones [9]. It was recently estimated that the visible production 
losses and vaccination costs in endemic countries alone is between US$6.5 and 21 
billion. Additionally, outbreaks in FMD free countries may cause losses of US$1.5 
billion per year [10]. The economic importance of being officially recognized by the OIE 
as a member country to the free of FMD without using vaccination list allows these 
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countries to freely export animals and animal products. The use of vaccination during an 
outbreak in a previously FMD free zone in order to regain disease-free status requires at 
least three more months when a vaccinate-to-live policy is enacted compared to stamping 
out or slaughter of vaccinated animals [11]. The reason for this delay might result from 
difficulty distinguishing infected from vaccinated animals (DIVA) and that vaccinated 
animals exposed to the virus may remain asymptomatic but become virus carriers 
potentially initiating new outbreaks [4] further complicating the process of regaining 
FMD-free status. 
The causative agent, foot-and-mouth disease virus (FMDV) is the type species of 
the genus Apthovirus in the family Picornaviridae [2]. FMDV consists of seven serotypes 
(A, O, C, SAT 1-3 and Asia1) and multiple strains within each serotype, which differ 
antigenically. Infection with one serotype usually results in protection from subsequent 
exposure to the same serotype but affords little, if any, cross-protection with other 
serotypes. Its genome is comprised of a single-stranded positive-sense RNA of about 8.5 
kb encoding a single long open reading frame (ORF). The polyprotein is processed post-
translationally to yield intermediate and mature structural and nonstructural (NS) 
proteins. The icosahedral protein capsid contains 60 copies each of 4 structural proteins 
(VP1–4), whose assembly is dependent on NS viral protein 3Cpro cleavage of the 
structural protein precursor, P1-2A [12]. 
The innate immune system, the first line of immune defense, is comprised of cells 
and mechanisms that defend the host from infection by FMDV in a non-specific manner 
through interactions of conserved viral motif with pattern recognition receptors. The 
innate immune responses are responsible for recruiting cells to the site of infection 
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through cytokines. These recruited cells are then responsible for activating the adaptive 
immune response, discuss below, through the process of antigen presentation. Disease 
occurs when FMDV succeeds in overwhelming innate host responses to establish a local 
site of infection, and then replicates there to allow its further transmission within the host. 
Infection of cattle generally occurs via the respiratory route by aerosolized virus but can 
also occur through abrasions on the skin or mucous membranes [13]. FMDV infects and 
replicates efficiently in epithelial cells, which contribute to the innate immune response 
through the production of interferons, chemokines and other cytokines. Recruitment of 
immune cells to the site of infection is mediated through chemokines [14]. In the current 
work, FMDV appears to induce expression of the CCL8 gene, an inflammatory mediator. 
The gene product of CCL8 is a chemokine that attracts and activates leukocytes. It is 
possible that the early induction of CCL8 in the protected cattle results in the recruitment 
of phagocytic antigen presenting cells to the site of infection where they encounter 
FMDV antigens. The reduction in gene expression of CCL8 at later time points might 
correlate with recruitment of these phagocytic antigen presenting cells to secondary 
lymphoid tissues, such as lymph nodes. These cells may then encounter the cognate 
receptor on a specific B or T lymphocyte for the antigen they are presenting. This antigen 
presentation can initiate the adaptive immune response which may result in protection 
from subsequent exposure. Genome replication and virion assembly occurs in the 
infected cell cytoplasm [14]. FMDV replication outpaces the host innate immune 
response because FMDV is able to shut down host de novo protein synthesis [14]. 
Epithelial cells contribute to the innate immune response to FMDV through the release of 
cytokines, including interferons. FMDV is highly susceptible to the action of interferon 
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type I in vitro [15] and in vivo [16]. Innate immune defenses can control FMDV, but it is 
still unclear to what extent such responses are induced during natural infection. Rapid 
control of viremia and early induction of adaptive immune responses would indicate 
innate immune responses are active. However, the characterization of such responses are 
not yet comprehensive. 
Virus clearance is dependent on specific neutralizing antibodies [17, 18], which 
are directed towards epitopes on the three external structural proteins [2]. Vaccine-
induced antibodies confer protection by neutralization and/or opsonization. In so doing, 
preventing entry into target cells and mediating degradation of virus by phagocytic cells 
through Fc receptor mediated uptake respectively [19, 20]. Vaccine-induced serotype-
specific protection is generally measured as a function of FMDV-specific neutralizing 
antibody titer [21, 22]. However, protection from disease has been reported in the 
absence of serum virus neutralization (SVN) titer [19, 21, 23], and vaccinated animals 
with medium to high neutralizing antibody titers may not always be protected [21]. 
Although neutralizing antibodies are an important component of vaccine-induced 
protection [24, 25]; other mechanisms of antibody-dependent protection likely exist that 
may inhibit viral maturation or release without affecting viral entry; thus, do not 
neutralize in vitro [25-28] but contribute to protection from reinfection or infection in the 
case of vaccination. 
The implication of cell-mediated immune responses in terms of protective 
immunity to FMDV remains unclear, though it has been suggested that secretion of IFN-
γ, a marker for development of cellular immunity which also has antiviral properties, may 
be important in controlling the virus in at least some animals [29, 30]. Additionally, the 
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enhanced efficacy of an Ad5-vectored FMD subunit vaccine correlated with an increase 
in IFN-γ producing T-cells following challenge when compared to challenged controls 
[31]. Although an MHC class I-restricted CD8+ T-cell response is induced by FMDV and 
inactivated FMDV [32], the correlation of circulating effector and memory CD8+ T-cells 
specific for FMDV and protection from disease remains to be well described [32]. The 
role of vaccine-induced antibodies in preventing infection for this intracellular pathogen 
may be more important than cellular immune functions. Thus, the immune response to 
FMDV and vaccination is likely shifted towards a Th2 response. Accordingly, a gap in 
our understanding of vaccine-induced protection following viral challenge exists and 
further understanding of the host’s immune response to vaccination and/or viral challenge 
may enhance progress towards development of effective tools and countermeasures for 
FMD. 
Traditional Chemically-inactivated FMD Vaccines 
Licensed traditional vaccines that induce immunity to FMD are chemically 
inactivated cell-culture-derived whole virus preparations emulsified with adjuvant [2, 
33]. These vaccines are most commonly used in enzootic areas and have been successful 
in reducing outbreaks worldwide [2, 33, 34]. Standard potency commercial vaccines are 
formulated with enough antigen and adjuvant to provide a minimum potency level of 3 
PD50 (50% protective dose) and provide six months of immunity when two initial doses 
are administered a month apart. Higher potency emergency vaccines are recommended 
for vaccination in naïve populations for wider range of immunity along with rapid 
induction of protection. These emergency vaccines are formulated to have a minimum 
potency level of 6 PD50. 
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The limitations of these vaccines include difficulty distinguishing infected and 
vaccinated animals, the need for high-containment manufacturing facilities to produce 
vaccine and inability to induce rapid protection [2, 34, 35].  
Adenovirus 
 
Adenoviruses are DNA viruses generally causing mild infection in the upper or 
lower respiratory tract, gastrointestinal tract, or conjunctiva [36]. Its double-stranded 
DNA genome is approximately 34-43 kb surrounded by a non-enveloped icosahedral 
protein capsid of approximately 90 nm. The tropism of adenoviruses is determined by 
their ability to associate with host cell receptors. Most human adenoviruses, including 
serotype 5, initially bind to the cocksackie adenovirus receptor (CAR) [37], which is 
expressed on many cell types, although lymphoid cells do not express CAR. 
Adenoviruses are highly immunogenic activating the innate immune system by 
expressing pathogen-associated molecular patterns (PAMPs). These PAMPs bind pattern 
recognition receptors (PRRs) on host cells, which includes receptors of the innate 
immune system, inducing proinflammatory cytokines and differentiation of immature 
dendritic cells into professional antigen presenting cells (APCs) [38]. 
Adenovirus-vectored Vaccines 
 
Adenoviruses have an efficient cell entry mechanism, are able to propagate to 
high titer and are capable of eliciting T and B cell responses to antigens encoded as a 
transgene product and the adenovirus vector itself [39-46]. Adenoviruses have 
demonstrated high efficiency as vehicles for introducing foreign DNA into target cells. 
Taken together, the intrinsic immunogenicity and ease of transducing foreign DNA, these 
features accompanied by extensive knowledge of adenovirus molecular biology and 
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methods for manipulating the viral genome that are now available, make adenoviruses 
appealing candidates for vaccine vector development [46]. 
Human Adenovirus-Vectored FMD Vaccines 
 
Traditional approaches to vaccine development for FMD is problematic for a 
number of reasons. Manufacturing these vaccines in countries where FMD is eradicated 
presents a moderate risk due to the possibility of incomplete inactivation or virus escape 
from high-containment vaccine-producing facilities. Traditional vaccines are generally 
incompatible with DIVA assays. Additionally, since FMDV is an RNA virus, repeated 
serial passage in culture would lead to antigenic variation making serial passage 
attenuation unappealing for vaccine development. The use of adenovirus vectors 
continues to eliminate the limitations of traditional approaches to FMD vaccine. The 
advantage of adenoviral-vectors is its ability to bind to and internalize in many cell types. 
This feature guarantees rapid uptake and expression of desired genes. Thus, acting as an 
efficient vehicle for transducing genetic material. 
A recombinant replication-defective human adenovirus serotype 5 vector 
containing FMDV capsid, P1-2A, and viral 3C protease coding regions was developed 
[35]. This construct was formulated with VaxLiant™ adjuvant [47] and was recently 
granted a conditional license [48]. This vaccine, Ad5-FMDV, has demonstrated to 
improve on some of the limitations of traditional FMD vaccines by allowing DIVA and 
they can be manufactured in the U.S. without the need for a high-containment facility 
[49]. 
Research Aim 
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Categorizing cattle on the parameters of seroconversion and protection status 
yields four groups of cattle. Two of these groups are the expected outcome, protected 
with SVN titer ≥1.2 and unprotected with SVN titer <1.2. The other two groups are the 
rare but unexpected outcome, unprotected with SVN titer ≥1.2 and protected with SVN 
titer <1.2. The current study examines these rare but unexpected outcomes. I sought to 
investigate the bovine immune response to Ad5-FMDV. In this study, I used microarray-
based analysis to examine the transcriptional response to Ad5-FMDV vaccination, 
adenovirus vector (ad-null) and FMDV challenge in bovine peripheral blood cells. I 
hypothesized that this method would provide a genomic tool for predicting vaccine 
efficacy in FMD vaccination and offer new insight into the immune response to 
vaccination and viral challenge. 
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2. Methods 
2.1 Animals and Treatment 
Holstein steers approximately 6 months old and weighing approximately 150 kg were 
housed in accordance with BSL3-Ag requirements. Procedures were conducted in 
accordance with the guidelines of the institutional animal care and use committee 
(protocol numbers 196-D-11, 232-11-D). Animals were administered a monovalent 
adenovirus-vectored foot-and-mouth disease (FMD) vaccine[48] with adjuvant 
(ENABL™, VaxLiant, Lincoln, NE) via IM route. Fourteen days post-vaccination 
(14dpv); animals were challenged with 104 TCID50 homologous virus via intradermal 
lingual (IDL) route [11]. Following viral challenge, animals were observed for signs of 
disease, defined as presence of pedal lesions within 14 days. Serum virus neutralization 
(SVN) test was performed according to the OIE standard [11]. Samples were categorized 
as high titer if the neutralizing titer was ≥1.2 and samples were categorized low titer if 
SVN titer was <1.2.  
 
2.2 Study Design 
I examined transcripts from peripheral blood cells at four sampling time points (fig. 2). 
Blood was collected on the morning prior to vaccination, 24 hours following vaccination, 
on the morning just prior to challenge (14 days post-vaccination) and 24 hours following 
challenge. RNA recovered from PBMCs was assessed for purity and integrity prior to any 
further downstream analysis. Gene expression analysis from two-color microarray 
hybridization was performed using an intensity-based approach allowing us to make 
multiple comparisons [50-52]. 
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2.3 Sample Collection 
Blood was drawn during routine husbandry and collected in a vacutainer venous blood 
collection plasma separating tube with polymer gel separator (Becton, Dickinson and 
Company, Franklin Lakes, NJ, p/n 367964). Blood samples were spun down at 1,200 x g 
for 10 min at room temperature. Buffy coats were collected using a transfer pipette and 
placed in a sterile 2 mL screw cap microcentrifuge tubes containing 1.2 mL RNALater 
(Life Technologies, Grand Island, NY, p/n AM7021). Microcentrifuge tubes were stored 
at 4°C overnight to allow RNALater to penetrate cells and then archived at -70°C. 
 
2.4 RNA Recovery 
An aliquot of 250 µL was placed in a 1.5 mL microcentrifuge tube containing an equal 
volume of sterile 1x PBS, mixed by pipetting and spun down at 1,500 x g for 10 minutes 
at room temperature. The supernatant was removed and RNA recovered utilizing the 
RNeasy mini kit following the animal cells spin protocol (Qiagen, Valencia, CA, p/n 
74106).  Samples were further purified and concentrated using the RNA Clean & 
Concentrator-5 kit (Zymo Research, Irvine, CA, p/n R1016). The product insert’s 
general protocol for total RNA was followed. Samples were then assessed for yield and 
purity on the NanoDrop ND-1000. 
 
2.5 RNA Integrity Assessment  
RNA samples were analyzed on the 2100 Bioanalyzer (Agilent Technologies, Inc., Santa 
Clara, CA, p/n G2940CA) utilizing the RNA 6000 nano kit (Agilent Technologies, Inc., 
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Santa Clara, CA, p/n 5067-1511) according to the manufacturer’s instructions. Samples 
with a minimum RIN of 7.5 were utilized in a microarray-based gene expression study.  
 
2.6 Microarray: RNA Amplification and Labelling  
Starting with 50ng total RNA, the Agilent two-color microarray-based gene expression 
analysis version 6.5 (agilent.com) protocol was followed. All incubations were performed 
utilizing a thermal cycler. The Agilent two-color low-input quick amp labeling kit (p/n 
5190-2306) was utilized for cDNA synthesis, in-vitro amplification and labelling of 
nucleic acids. Purification of labelled cRNA was performed with the Qiagen RNeasy 
mini kit (p/n 74104). 
 
2.7 Microarray: Fragmentation and Hybridization 
Fragmentation of purified cRNA was performed with the Agilent gene expression 
hybridization kit (p/n 5188-5242). Fragmented cRNA samples were assembled with the 
Agilent hybridization gasket (p/n G2534-60012), Agilent bovine gene expression 
microarray (p/n G2519F, design id: 023647) and Agilent hybridization chamber (p/n 
G2534A). The assembled hybridization chambers were placed in a rotating hybridization 
oven set to 65°C with 10 rpm rotation. 
 
2.8 Microarray: Scanning and Feature Extraction 
Following washing, the slides were immediately scanned on a GenePix 4000B laser 
scanner (Molecular Devices). Photo multiplier tube (PMT) gains were adjusted to 
produce count ratios (cy5/cy3) of approximately 1 (0.9 – 1.1) with no more than 1x10-3 of 
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the normalized counts at saturating intensity. Feature extraction was performed with 
GenePixPro 7 software (Molecular Devices). Microarray images were visually inspected 
to identify artefacts on features that suggest environmental contaminants and other non-
biological fluorescence and excluded them from downstream analysis. Background 
fluorescence for each feature was determined as the mean of the median values for the 
five closest negative control features. Intensity values for each feature’s channel were 
calculated as the median fluorescence value minus the calculated background value.  
 
2.9 Microarray-data Analysis 
In-silico Experimental Setup: 
Each channel’s background-corrected median fluorescence value (532 and 635 nm) was 
used in an intensity-based analysis utilizing Agilent GeneSpring software (v.12.5). 
Feature-level quantile normalization was performed on all the background-corrected 
intensity values and samples were grouped according to days-post-vaccination, SVN titer 
and protection status. Features were included in analysis if ≥80% of the features across 
the replicates were available in all of the time points for a given gene target. Features 
were excluded if they were at saturating intensity or flagged “bad” in the GenePix 
software. Because some genes were represented by duplicate or triplicate features on the 
microarray slide, gene-level analysis was performed using mean values of replicate 
features. Quantile normalization was then performed on the gene-level in-silico 
experiment. 
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Identifying Differentially Expressed Genes: 
Genes were identified as differentially expressed if there was at least a two-fold change 
between time points of interest and if those changes were statistically significant (p-value 
≤0.05). All grouped samples were representative of four time points (0, 1 days post 
vaccination and 0, 1 days post challenge). For the purpose of identification of 
differentially expressed genes, samples were interpreted and grouped according to any of 
the following: a.) protected/not protected, b.) high SVN/low SVN, c.) protected High 
SVN/protected low SVN/not protected high SVN/not protected low SVN. 
 
2.10 Real-Time PCR  
The primers and probes for TaqMan RT-qPCR assay were designed utilizing Beacon 
Designer 8 (Premier Biosoft International, Palo Alto, CA) with the program’s default 
settings. The internal control genes were selected based on reported stability of 
transcripts from bovine lymphocytes [53]. PCR reactions were created in triplicate 
utilizing the TaqMan Fast Virus 1-Step Master Mix (Life Technologies, Grand Island, 
NY, p/n 4444436) at final primer and probe concentrations of 500 nM and 100 nM 
respectively. Thermal cycling method consisted of the following: 50°C for 20 min, 95°C 
for 8 min, 50 cycles of [95°C for 15 sec, 60°C for 1 min]. Fold change was calculated via 
the 2(-delta delta C(T)) method [54]. 
 
2.11 Magnetic Activated Cell Sorting 
Blood samples from cattle were separated into populations of single cell types according 
to cell surface markers utilizing the magnetic activated cell sorting system with LS 
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columns (P/N 130-042-401, Miltenyi Biotec, San Diego, CA) and Goat anti mouse IgG 
microbeads (p/n 130-048-401, Miltenyi Biotec, San Diego, CA) according to the 
procedure in the product manual. WC1+ γδ T-cells were positively selected with a mouse 
anti bovine WC1 monoclonal antibody (p/n IL-A29, VMRD, Pullman, WA). CD14+ 
cells were then positively selected with a mouse anti bovine CD14 monoclonal antibody 
(p/n MM61A, VMRD, Pullman, WA). Following these two rounds of cell sorting, T-cells 
and B-cells were depleted utilizing mouse anti bovine CD3 (p/n MM1A, VMRD, 
Pullman, WA) and CD21 (p/n GB25A, VMRD, Pullman, WA) antibodies respectively. 
The remaining population of negatively-selected cells were enriched for natural killer 
cells. 
 
2.12 Indirect Immunofluorescence Assay 
Five hundred µL of diluted cells was applied to a glass slide. Samples were spun down at 
800 rpm for 3 minutes in the cytospin. Cells were then fixed with ice-cold acetone. 
Samples were incubated with primary antibody for approximately one hour at 37°C. 
Primary antibodies were as follows:  
• WC1+ γδ T-cells: mouse anti bovine TcR1-N24 (δ chain) (p/n GB21A, VMRD, 
Pullman, WA) 
• CD14+ cells: mouse anti bovine CD172a (p/n MCA2041G, AbD Serotec, 
Raleigh, NC) 
• NK cells: mouse anti bovine CD335 (NKp46) (p/n MCA2365EL, AbD Serotec, 
Raleigh, NC) 
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Following washing, samples were incubated with secondary antibodies for one hour at 
37°C. Secondary antibody was goat anti mouse conjugated with either Alexa Flour® 594 
(p/n A-21145, Life Technologies, Grand Island, NY) or Alexa Flour® 488 (p/n A-11017, 
Life Technologies, Grand Island, NY). Following washing and air drying, ProLong® 
Gold antifade reagent with DAPI (p/n P-36931, Life Technologies, Grand Island, NY) 
was applied. 
 
2.13 ELISA 
Capture ELISA for CCL8 (MCP-2) was performed using plasma from cattle to determine 
if this protein could be detected in vivo. The procedure in the product manual was 
followed (p/n sE90088Bo, USCN Life Science Inc., Houston, TX). 
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3. Results  
 
3.1 RNA Assessment 
 
RNA samples from PBMC passing the RNA quality criteria [A260/280 ratio = 2.0 ± 0.2; 
RNA integrity number (RIN) > 7.5 as assessed using the eukaryotic RNA 6000 kit on the 
Agilent 2100 Bioanalyzer] were utilized for microarray-based gene expression analysis or 
RT-qPCR. The average 260/280 ratio was 2.08 and the average RIN was 9.3. 
 
3.2 Indirect Immunofluorescence Assay 
Light microscopy visual inspection of slides revealed >90% of the adhered cells were 
positively-selected WC1+ γδ T-cells. Similar results were observed with positively 
selected CD14+ cells. Visual inspection of the slides for the negatively-selected cell 
population revealed approximately 60% of the adhered cells were CD335+ (NKp46) 
natural killer cells. 
 
3.3 Microarray-based gene expression analysis 
Following amplification and labelling, cRNA samples were purified and assessed on the 
NanoDrop to determine yield and incorporation of cyanine dye (specific activity). 
Median background-corrected intensity values from microarray features were imported 
into GeneSpring software (v.12.5) and grouped according to clinical outcome 
(protected/not protected) with an additional group for cattle receiving the ad-null vaccine 
vector lacking the transgene. Differential expression was determined between time points 
representing the innate (0,1 days post vaccination), adaptive (0,14 dpv), 
immunoregulatory (1,14 dpv) and viral responses (0,1 days post challenge)(fig 2). An 
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arbitrary group of 12 gene transcripts was validated using RT-qPCR and the expressions 
patterns were similar to those obtained from microarray-based analysis. Among the 
protected group, chemokine (C-C motif) ligand 8 (CCL8) was the most up-regulated gene 
at 1 dpv. Unprotected cattle demonstrated a mild increase of CCL8 following 
vaccination. Following this increase in protected cattle at 1dpv, CCL8 expression levels 
returned to baseline prior to viral challenge whereas the converse was observed in 
unprotected cattle. Thus, I considered the possibility of using this transcript as an 
indicator of vaccine-induced protection. 
 
The CCL8/MCP-2 gene expression pattern in cattle administered the Ad-null vaccine had 
a similar pattern as the protected cattle administered the vaccine candidate. These ad-null 
vaccinated cattle seroconverted to the viral vector and as expected, were not protected 
from FMD. Whereas 18/21 of cohorts in the same study that were administered the 
vaccine candidate were protected from FMD (data not shown). The adenovirus vaccine 
vector induces a primary innate immune response thereby increasing expression of 
inflammatory mediators setting the stage for an efficacious adaptive immune response to 
the transgene product. This microarray-based observation suggests that our reported 
expression profile for CCL8/MCP-2 correlates with protection. 
 
An additional microarray-based gene-expression study was performed on cattle 
administered a traditional inactivated vaccine for comparison to Ad-5 FMDV. The 
number of genes induces by vaccination with a traditional inactivated FMD vaccine is 
much fewer than compared to an adenovirus-vectored FMD vaccine. Additionally, sorted 
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cells into one of three individual cell types and observed gene expression patterns in 
WC1+ γδ T-cells, CD14+ cells and CD335+ NK cells that were different than the gene 
expression pattern in the heterogeneous PBMC population.  
  
3.4 RT-qPCR 
Real-time quantitative PCR using a TaqMan probe was performed as an independent 
assay to verify microarray-based gene expression results. Multiple internal control genes 
were selected based on reported stability of internal control genes from bovine 
lymphocytes [53]. Twelve immune response genes were chosen because of their robust 
changes in gene expression in the protected cattle that demonstrated a low SVN titer, 
suggesting an important role contributing to protection. The mRNA expressions of these 
12 chosen immune response genes demonstrated similar behavior as detected expression 
changes by microarray analyses. Because of limited biological samples available, RT-
qPCR verification of microarray data was unable to be performed on some of the 
samples. 
 
An additional RT-qPCR study was performed with multiplexed primers for the CCL8 and 
RPS24 gene to increase the sample size into the investigation of the correlation between 
protection and relative gene expression patterns of the CCL8 gene. This study included 
32 protected animals and 7 unprotected animals which were not previously analyzed by 
microarray-based analysis. In addition, 4 ad-null control animals which were previously 
analyzed were also included. I found that the correlation of CCL8 transient up-regulation 
and protection was not observed in this larger sample set. 
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3.5 ELISA 
The sensitivity of this commercially available kit was 6.4 pg/mL with a detection range 
of 15.625–1000 pg/mL. Utilizing the standard in the kit, the standard curve had a R2 
value of 0.9859. The plasma from a representative sample all cattle analyzed via 
microarray was assessed with this kit. There was no signal detected above background 
from any of the cattle administered the Ad5-FMDV. The protein levels of CCL8 in 
plasma from cattle administered an ad-null vaccine was decreasing. The protein levels for 
cattle administered sham vaccination with formulation buffer demonstrated an increase in 
protein levels.  
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4. Discussion 
FMD is one of the most economically devastating diseases of the livestock 
industry worldwide. Production losses have a large impact where the poorest are most 
dependent on livestock. Direct losses limit livestock productivity degrading food security. 
Countries with ongoing control programs spend a lot of money on FMD control and 
management. The threat, let alone presence, of FMD prevents access to lucrative 
international markets [10]. Although the U.S. has been free of FMD since 1929, the 
presence of FMD in a number of FMD-free countries and the potential as a bio-terrorist 
threat have significantly increased public awareness of, and interest in this disease [55-
58].  
Although traditional inactivated FMD vaccines have been efficacious in reducing 
outbreaks worldwide, the need for high-containment facilities to manufacture, 
incompatibility with DIVA assays and the need to stockpile large quantities of doses for 
emergency purposes make traditional vaccine approaches unfavorable. Adenovirus-
vectored FMD (Ad-5 FMD) vaccines, improve on some of the short-comings of 
traditional inactivated FMD vaccines by allowing DIVA and do not require high-
containment facilities for manufacturing. Additionally, the adenovirus vaccine vector can 
be quickly manufactured with the coding region from any serotype, thereby 
circumventing the need to stockpile many doses. 
Vaccines that provide long-lasting immunity stimulate both the innate and 
adaptive arms of the immune system. The innate immune system is responsible for 
shaping the nature of the adaptive immune response in terms of its intensity, duration and 
tailoring of immunological memory. The interplay between antigen presenting cells, B 
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cells, T helper and killer subtypes, and regulatory T- and B-cells responses is critical for 
generating a robust immune response and immunological memory against infectious 
diseases [59-61]. Adjuvants for vaccines should be strategically selected to elicit some of 
these specific observations that are responsible for shaping the immune response to 
vaccine + adjuvant that leads to immunity. 
The importance of vaccine-induced FMD virus-specific neutralizing antibodies is 
well known. However, protection from disease does not always correlate with presence of 
specific neutralizing antibodies [19]. Transcriptomic analysis, with DNA microarray 
technology, of purified peripheral blood mononuclear cells (PBMCs) reveals that FMD-
protected cattle demonstrate a transient induction of genes in response to Ad-5 FMDV 
vaccination that gene ontology suggests were associated with a stress response. One gene 
in particular was selected to be more closely studied. Monocyte chemoattractant protein 2 
(MPC-2), a chemotactic cytokine that activates many types of immune cells involved in 
the inflammatory response, was assayed in a larger group of cattle (n=39) not previously 
studied with DNA microarray. 
The reported expression profile of CCL8/MCP-2 appears to correlate with the 
profile of the immune response to the adenovirus vaccine vector. I expected the 
adenovirus vector to be immunogenic, as it was, and when the vector was combined with 
the FMDV transgene product, cattle developed immunological memory that seemed to be 
denoted at the gene expression level by a more robust immune response compared to ad-
null. The gene expression levels of CCL8/MCP-2 correlated with the intensity of the 
immune response, suggesting that when CCL8/MCP-2 levels do not significantly 
increase following vaccination, the immune response to the vaccination was insufficient 
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to confer protection. The use of RT-qPCR to profile gene expression of CCL8/MCP-2 
has the potential to enhance the prediction of vaccine-induced protection when used as an 
adjunctive assay along with SVN. 
When this study was expanded to increase the sample size, the correlation was not 
observed in this larger sample size. Although I also investigated a shorter time point 
following vaccination (7dpv) in order to determine if the previous correlation in the 
microarray-based study occurred prior to 14dpv, that data merely added an additional 
time point. 
The significance of this work is that it outlines a systematic process for 
investigating the immune response to vaccination through a transcriptomics approach. A 
list of genes that correlated with protection was generated (Table 3) and one gene, 
CCL8/MCP-2, was chosen for a thorough examination. Although this additional study 
did not come to fruition, there are other genes on that list that may be of significance. It 
may be possible that transient up-regulation of CCL8 mRNA contributes to protection 
with other mechanistic immune functions that supplement or co-correlate with protection. 
Perhaps transient up-regulation of CCL8 is one of multiple biomarkers that contribute to 
protection. Once the biological underpinnings of protection are better understood perhaps 
these complex correlates of vaccine-induced protection will be readily identified.  
Although the role of neutralizing antibodies should be considered in the context of 
factors that correlate with protection in alternative, additive, or synergistic ways rather 
than the sole correlate of protection [62], at present SVN titer is still the most reliable 
assay readout to predict vaccine efficacy prior to, or in the absence of, viral challenge. 
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Figures 
Figure 1 – Indirect Immunofluorescence Assay 
*Images are representative  
 
 WC1 Positively selected γδ T-
cells. Primary antibody, mouse 
anti-bovine WC1. Secondary 
goat anti-mouse Alexa 488 
conjugated. 
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 WC1 Positively selected γδ T-
cells. Primary antibody, mouse 
anti-bovine δ chain. Secondary 
antibody, goat anti-mouse Alexa 
594 conjugated. 
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WC1 Positively selected γδ T-
cells, DAPI stained 
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Monocytes: staining for CD14 @ 488nm   
CD14 positively selected 
monocytes. Primary antibody 
mouse anti-bovine CD14. 
Secondary antibody, goat anti-
mouse Alexa 488 conjugated. 
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CD14 positively selected 
monocytes. Primary antibody 
mouse anti-bovine CD172. 
Secondary antibody, goat anti-
mouse Alexa 594 conjugated. 
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CD14 positively selected 
monocytes, DAPI stained 
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 WC1, CD14, CD3, CD21 
depleted, negatively selected 
natural killer cells. Primary 
antibody, mouse anti-bovine 
CD335 (NKp46). Secondary 
antibody, goat anti-mouse Alexa 
488 conjugated. 
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  WC1, CD14, CD3, CD21 
depleted, negatively selected 
natural killer cells, DAPI 
stained. 
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Figure 2 – CCL8/MCP-2 Expression Profiles 
  
            
  CCL8/MCP-2 log(2) fold change   
    
  Microarray 1 2 3   
  High SVN, Protected 3.66 -4.49 2.69   
  Low SVN, Protected 2.36 -3.96 6.51   
  High SVN, Unprotected 0.36 1.41 3.5   
  Low SVN, Unprotected 0.5 0.42 4.09   
  Ad-Null, Unprotected 0.37 -1.63 6.88   
  RT-qPCR         
  High SVN, Protected 4.55 -3.68 4.79   
  Low SVN, Protected 5.95 -7.13 8.05   
  High SVN, Unprotected -0.09 1.1 6.82   
  Ad-Null, Unprotected 2.63 -2.73 7.02   
    
            
(1) log2 fold change at 1dpv 
compared to 0dpv 
(2) log2 fold change at 14dpv 
compared to 1dpv 
(3) fold change at 1dpc compared to 
0dpc 
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Normalized intensity values 
from microarray over time 
course of vaccine efficacy 
study. Protected (n=5), not 
protected (n=4), ad-null (n=4) 
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Figure 3 – Microarray-based Differential Expression 
  Microarray-based log(2) fold change results           
  
High SVN, 
Protected 
Low SVN, 
Protected   
  interval: 1 2 3 interval: 1 2 3   
  APOBEC3A 1.26 -0.94 2.03 APOBEC3A 1.67 -1.79 4.34   
  CCL8 3.66 -4.49 2.69 CCL8 2.36 -3.96 6.51   
  GBP5 -0.14 -0.24 -0.25 GBP5 1.01 -2.00 3.48   
  IL8 0.53 -1.39 2.97 IL8 0.08 2.62 -0.48   
  IL10 0.60 -0.30 0.07 IL10 -0.44 0.16 0.96   
  IL16 -0.34 0.49 -0.24 IL16 0.48 -0.77 0.28   
  ISG15 1.53 -1.91 1.60 ISG15 1.53 -1.40 4.04   
  MX2 0.81 -1.35 0.58 MX2 1.00 -1.41 2.43   
  OAS2 0.53 -0.73 0.18 OAS2 2.33 -1.61 2.72   
  TLR3 -0.38 0.16 -0.06 TLR3 0.11 -0.94 1.04   
  TLR4 0.88 -1.21 1.36 TLR4 0.45 0.51 1.30   
  TLR10 -0.48 1.04 -0.62 TLR10 1.00 -1.41 0.95   
  
High SVN, 
Unprotected 
Low SVN, 
Unprotected   
  APOBEC3A 0.61 -0.46 1.63 APOBEC3A -0.69 2.15 0.29   
  CCL8 0.36 1.41 3.50 CCL8 0.50 0.42 4.09   
  GBP5 -0.06 -0.38 2.70 GBP5 -1.28 0.43 0.54   
  IL8 0.76 0.26 0.15 IL8 0.29 1.20 0.82   
  IL10 0.55 0.57 -0.04 IL10 -1.64 0.95 1.52   
  IL16 0.03 -0.07 -0.23 IL16 0.45 -0.77 0.23   
  ISG15 0.18 -0.04 2.36 ISG15 0.26 0.56 1.21   
  MX2 -0.03 -0.32 2.67 MX2 0.19 0.26 0.20   
  OAS2 -0.50 -0.26 2.93 OAS2 -0.67 1.04 -0.34   
  TLR3 0.03 -0.20 0.29 TLR3 -0.14 -0.58 0.24   
  TLR4 0.84 0.44 -1.24 TLR4 -0.53 1.75 0.75   
  TLR10 -0.14 -0.44 0.59 TLR10 1.03 -0.95 -0.45   
          
 
  
(1) log2 fold change at 1dpv compared to 0dpv 
(2) log2 fold change at 14dpv compared to 1dpv 
(3) fold change at 1dpc compared to 0dpc 
 - 43 - 
 
  Microarray-based log(2) fold change results 
  interval: 1 2 3   
  Ad-Null   
  APOBEC3A 0.7 -0.48 4   
  CCL8 0.37 -1.63 6.88   
  GBP5 0.29 -0.4 1.7   
  IL8 -2.42 0.63 0.14   
  IL10 -0.7 -0.24 0.25   
  IL16 0.26 0.18 -0.58   
  ISG15 0.41 -1.22 4.19   
  MX2 0.74 -1.04 3.69   
  OAS2 1.25 -0.96 3.88   
  TLR3 0.31 0 0.11   
  TLR4 -0.95 -0.08 1.81   
  TLR10 0.72 -0.32 0.01   
*intervals 1,2 & 3: 0/1dpv, 1/14dpv & 0/1dpc respectively 
 
 
 
  
(1) log2 fold change at 1dpv compared to 0dpv 
(2) log2 fold change at 14dpv compared to 1dpv 
(3) fold change at 1dpc compared to 0dpc 
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Figure 4 – RT-qPCR verification of microarray-based data 
                      
  RT-qPCR log(2) fold change results   
  
High SVN, 
Protected 
Low SVN, 
Protected   
  interval: 1 2 3 interval: 1 2 3   
  APOBEC3A 1.66 -1.72 1.93 APOBEC3A 4.06 -2.95 5.04   
  CCL8 4.55 -3.68 4.79 CCL8 5.95 -7.13 8.05   
  GBP5 0.14 0.15 -0.01 GBP5 2.82 -3.40 2.83   
  IL8 0.54 -2.33 3.20 IL8 1.51 1.01 0.95   
  IL10 -0.04 -1.29 2.54 IL10 0.94 0.83 -0.11   
  IL16 -0.33 -0.23 -0.41 IL16 1.40 -2.17 0.31   
  ISG15 0.98 -1.96 1.82 ISG15 3.26 -2.46 3.82   
  MX2 0.83 -2.31 0.65 MX2 3.38 -4.27 3.43   
  OAS2 0.70 -1.88 1.07 OAS2 3.80 -4.35 4.57   
  TLR3 -0.04 -0.22 -0.27 TLR3 2.00 -2.49 0.77   
  TLR4 0.82 -1.92 1.20 TLR4 1.89 -1.41 1.59   
  TLR10 -0.49 -0.03 -0.73 TLR10 2.69 -2.31 0.44   
  
High SVN, 
Unprotected 1 2 3 Ad-Null 1 2 3   
  APOBEC3A 0.28 -1.61 3.36 APOBEC3A 1.86 -2.12 4.25   
  CCL8 -0.09 1.10 6.82 CCL8 2.63 -2.73 7.02   
  GBP5 -0.36 -1.19 2.84 GBP5 1.63 -1.67 2.92   
  IL8 0.27 -0.06 0.37 IL8 0.11 -1.53 0.91   
  IL10 1.20 0.97 -0.46 IL10 -3.98 0.86 0.64   
  IL16 0.17 -0.54 0.11 IL16 0.78 -1.78 0.14   
  ISG15 -0.87 -1.47 5.42 ISG15 1.38 -2.29 5.08   
  MX2 -0.58 -1.33 5.07 MX2 1.92 -3.74 4.64   
  OAS2 -0.74 -2.76 5.44 OAS2 1.88 -3.06 4.37   
  TLR3 -0.18 -1.10 0.70 TLR3 1.20 -1.60 0.81   
  TLR4 0.22 -0.33 1.49 TLR4 -0.23 -1.96 2.30   
  TLR10 -0.11 -1.33 0.84 TLR10 0.99 -0.66 0.50   
    
  
*intervals 1,2 & 3: 0/1dpv, 1/14dpv & 0/1dpc 
respectively         
 
  
(1) log2 fold change at 1dpv compared to 0dpv 
(2) log2 fold change at 14dpv compared to 1dpv 
(3) fold change at 1dpc compared to 0dpc 
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Figure 5 – CCL8 ELISA from Plasma & Standard Curve 
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F  igure 6 – RT-qPCR-based Differential Expression of CCL8 mRNA 
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Tables 
Table 1 – Primers and TaqMan Probes 
Gene APOBEC3A Gene ISG15 
Accession NM_001163936 Accession NM_174366 
Forward CTGACTGAGCATACCATC Forward GAGCTGAAGCAGTTCATC 
Reverse CCTTGATTGTTGAAGTTCTC Reverse GATGGAGATGCAGTTCTG 
Probe TATTCGTCCATCAGGTGTCGTCC Probe CCAGAAGATCAATGTGCCTGCTT 
Gene CCL8 Gene MX2 
Accession NM_174007 Accession NM_173941 
Forward GGTCCAGACTTCCATAAG Forward GCCTTTGAAGTACAAGAG 
Reverse GGCCATTATAATACAATAATACAC Reverse AGCTGATTGAAGTTGTTG 
Probe CGAACACCGAAGCCTTGAACC Probe CTCAGACTTCCACTCAGCACCA 
Gene GBP5 Gene OAS2 
Accession NM_001075746 Accession NM_001024557 
Forward TCTGGAGAATTCACTGAG Forward CTCACCTCTTGTCTCTTC 
Reverse CCAGATCATCATTATGTAGTG Reverse CTGCTGATGTCCATCTAA 
Probe AGGCACCAACCAGCATCTTCA Probe TATCTCAACAGTCACAATCCAAGCCT 
Gene IL8 Gene TLR3 
Accession NM_173925 Accession NM_001008664 
Forward CCAGAAGAAACCTGACAA Forward CTGGAGTATAATAACATAGAGC 
Reverse CGAAGTTCTGTACTCATTC Reverse CAGTGAAATGCTTTGTCTA 
Probe AAGCCTCTTGTTCAATATGACTTCCAA Probe TCAAGTCCAGGCGTCTCAAGTT 
Gene IL10 Gene TLR4 
Accession NM_174088 Accession NM_174198 
Forward CGGAAATGATCCAGTTTTAC Forward CAGAGCCTTTAGATATGGA 
Reverse AGCTCACTGAAGACTCTC Reverse GGTGGAAATAGAACTTGTAG 
Probe TTCTCCACCGCCTTGCTCTT Probe TACCACAGACACCAGGAGCAC 
Gene IL16 Gene TLR10 
Accession NM_001075253 Accession NM_001076918 
Forward CAGAGCTAAGAGAATACAC Forward GCATCAATGGACTCAGAC 
Reverse CAAGGAGATAACCGATTG Reverse CAGGCAGAATCATGTTCA 
Probe CGGAAGCCAACGACTGTGAC Probe AGGAAGACAACTCAGGAACAACTCA 
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Gene YWHAZ Gene PPIA 
Accession NM_174814 Accession NM_178320 
Forward CTGGTGATGACAAGAAAG Forward GTCCATCTATGGCGAGAA 
Reverse GGAGTTCAGAATCTCATAATAG Reverse ATGCCCTCTTTCACCTTG 
Probe CCAGTCACAGCAAGCATACCAAG Probe TGCCATCCAACCACTCAGTCTT 
Gene RPS24   
Accession NM_001025339   
Forward GAACGCAAGAACAGAATG   
Reverse GCACAATCACCACAGATA   
Probe ACTCCTTCTGTTGTCCAATCTCCA   
 
Multiplexed CCL8 
Gene CCL8 Gene RPS24 
Accession NM_174007 Accession NM_001025339 
Forward GGTCCAGACTTCCATAAG Forward GAACGCAAGAACAGAATG 
Reverse GGCCATTATAATACAATAATACAC Reverse GCACAATCACCACAGATA 
Probe CCGAACACCGAAGCCTTGAAC Probe ACTCCTTCTGTTGTCCAATCTCCA 
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Table 2 – Gene List & Internal Controls 
Gene List 
1. Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A 
2. Chemokine (C-C motif) ligand 8, also known as monocyte chemoattractant 
protein 2 (MCP-2) 
3. Guanylate binding protein 5 
4. Interleukin 8 (IL-8), also known as neutrophil chemotactic factor 
5. Interleukin-10 (IL-10), also known as cytokine synthesis inhibitory factor 
(CSIF) 
6. Interleukin-16 (IL-16), previously known as lymphocyte chemoattractant factor 
(LCF) 
7. Interferon-induced 17 kDa protein 
8. Interferon-induced GTP-binding protein Mx2 
9. 2'-5'-oligoadenylate synthetase 2 
10. Toll-like receptor 3 (TLR3) also known as CD283 
11. Toll-like receptor 4 (TLR4) 
12. Toll-like receptor 10, also designated as CD290 
Internal Control Genes 
1. Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, 
zeta polypeptide 
2. Peptidylprolyl isomerase A also known as cyclophilin A or rotamase A 
3. 40S ribosomal protein S24 
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Table 3 – Candidate Surrogate Markers for Protection 
Description Symbol Entrez Gene Fold Change 1dpv Accession No. 
Chemokine (C-C motif) ligand 8 CCL8 788169 4.6000476 NM_174007 
Collagen, type I, alpha 1 COL1A1 282187 2.0105424 NM_001034039 
Drebrin 1 DBN1 505406 8.14972 NM_001045917 
PREDICTED: Exonuclease 3'-5' domain containing 2 EXD2 539532 7.7476177 XM_587937 
Hyaluronan and proteoglycan link protein 3 HAPLN3 515224 7.0904818 NM_001098981 
5-hydroxytryptamine (serotonin) receptor 4 HTR4 317708 3.5694902 NM_001040485 
Katanin p60 subunit A-like 1, isoform 2 KATNAL1 537739 7.1488013 NM_001192918 
Meprin A, beta MEP1B 540701 3.7190018 NM_001144098 
N-acetyl-glucosaminyltransferase, isozyme B MGAT5B 785213 5.833619 NM_001102337 
Nudix (nucleoside diphosphate linked moiety X)-type motif 13 NUDT13 504993 6.997903 NM_001045905 
Ribosomal protein S6 kinase, 90kDa, polypeptide 2 RPS6KA2 517953 4.665269 NM_001192478 
  Fold change at 1dpv compared to 
0dpv in protected cattle with low 
SVN titer at time of challenge. 
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Table 4 – Serum Virus Neutralization Titer 
a.) SVN FMDV 
ET# 0 dpv 7 dpv 14 dpv 7 dpc 14 dpc 
D10-100 0.6 1.8 2.1 2.4 2.7 
D10-109 0.6 0.9 1.8 1.8 2.1 
D10-121 0.6 1.2 2.1 2.4 3 
D10-132 0.6 0.9 1.8 1.2 2.4 
D10-115 0.6 0.6 0.6 2.4 2.7 
D10-173 0.6 1.2 1.2 3 2.4 
D10-184 0.6 1.2 1.8 3 3.3 
D10-186 0.6 1.2 1.5 3.3 3 
D10-101 0.6 0.6 0.6 2.1 3 
D10-113 0.6 0.6 0.6 2.1 3 
D10-118 0.6 0.6 0.6 2.1 2.4 
D10-131 0.6 0.6 0.6 2.1 3 
D10-133 0.6 0.6 0.6 2.1 3 
D12-55 0.6 1.2 1.5 3.0 2.4 
D12-56 0.6 1.8 2.7 3.0 3.3 
D12-57 0.6 1.5 2.1 3.3 3.0 
D12-58 0.6 2.4 2.4 2.7 3.3 
D12-59 0.6 2.1 2.7 2.7 3.3 
D12-60 0.6 0.6 1.8 3.0 3.3 
D12-62 0.6 1.5 2.1 2.7 2.7 
D12-63 0.6 1.5 2.1 3.0 3.3 
D12-64 0.6 1.5 2.4 2.7 3.0 
D12-65 0.6 1.8 3.0 3.3 3.6 
D12-66 0.6 1.8 2.1 3.0 3.3 
D12-68 0.6 0.6 0.9 2.1 3.6 
D12-69 0.6 1.5 2.1 3.0 3.6 
D12-70 0.6 2.4 2.7 3.0 3.6 
D12-72 0.6 0.9 1.8 3.6 3.0 
D12-73 0.6 1.5 2.7 3.0 3.3 
D12-75 0.6 0.9 2.4 2.4 3.3 
D12-76 0.6 0.6 0.6 3.0 2.7 
D12-77 0.6 1.8 2.7 3.3 3.3 
D12-78 0.6 1.2 2.4 2.4 3.6 
D12-79 0.6 2.4 3 3 3.3 
Log10 of inverse 
two-fold 
dilution of 
inactivated sera 
capable of 50% 
reduction of 
cytopathic effect 
on BHK cells 
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b.) SVN Adenovirus-5 
ET# 0 dpv 7 dpv 14 dpv 7 dpc 14 dpc 
D10-100 0.6 1.5 2.1 2.4 1.8 
D10-109 0.6 0.9 3 2.7 2.7 
D10-121 0.6 1.2 3 2.4 2.7 
D10-132 0.6 1.5 3 2.7 2.4 
D10-115 0.6 1.2 1.8 2.7 2.4 
D10-173 0.6 1.8 3 3 2.1 
D10-184 0.6 0.6 2.7 3 3 
D10-186 0.6 1.8 2.7 2.4 2.4 
D10-101 0.6 1.5 2.4 2.4 2.4 
D10-113 0.6 0.6 0.6 0.6 0.6 
D10-118 0.6 0.6 0.6 0.6 0.6 
D10-131 0.6 0.6 0.6 0.6 0.6 
D10-133 0.6 0.6 0.6 0.6 0.6 
D12-97 0.6 0.6 0.6 2.1 3.3 
D12-98 0.6 0.6 0.6 2.4 3 
D12-99 0.6 0.6 0.6 2.4 3 
D12-100 0.6 0.6 0.6 2.4 3 
D12-101 0.6 1.2 1.8 2.7 3.3 
D12-104 0.6 1.8 1.5 3 3 
D12-106 0.6 1.2 1.8 3 3 
D12-107 0.6 0.6 0.6 3 2.7 
D12-108 0.6 1.2 1.8 3 3 
D12-109 0.6 0.6 1.2 3 3 
D12-110 0.6 0.6 1.2 3 3 
D12-111 0.6 0.6 1.2 3 3 
D12-112 0.6 1.2 1.5 3 3 
D12-113 0.6 0.6 1.2 2.4 3 
D12-114 0.6 1.8 1.8 3 3 
D12-115 0.6 1.2 1.8 3 3 
D12-116 0.6 1.2 1.5 3 3 
D12-117 0.6 1.5 1.2 3 3.6 
D12-118 0.6 1.8 1.8 2.7 3.3 
D12-119 0.6 0.6 1.5 3 3.3 
D12-120 0.6 1.8 1.8 2.4 3 
D12-121 0.6 1.2 1.8 3 3 
 - 53 - 
 
      
D12-55 0.6 0.6 0.6 0.6 0.6 
D12-56 0.6 2.1 2.4 2.4 2.1 
D12-57 0.6 1.5 2.4 3.3 2.1 
D12-58 0.6 1.8 2.4 3.0 2.7 
D12-59 0.6 1.5 2.4 1.8 2.1 
D12-60 0.6 1.5 2.4 1.5 2.1 
D12-62 0.6 1.5 2.4 2.4 2.4 
D12-63 0.6 0.6 0.6 0.6 0.6 
D12-64 0.6 0.6 0.6 0.6 0.6 
D12-65 0.6 2.1 2.1 2.1 2.7 
D12-66 0.6 1.2 2.7 2.4 2.4 
D12-68 0.6 0.6 0.6 0.6 0.6 
D12-69 0.6 0.6 0.6 0.6 0.6 
D12-70 0.6 0.6 0.6 0.6 0.6 
D12-72 0.6 0.6 0.6 0.6 0.6 
D12-73 0.6 0.6 1.8 1.8 1.8 
D12-75 0.6 0.6 0.6 0.6 0.6 
D12-76 0.6 0.6 0.6 0.6 0.6 
D12-77 0.6 2.4 2.1 2.7 2.7 
D12-78 0.6 1.2 2.4 2.4 1.8 
D12-79 0.6 0.6 0.6 0.6 0.6 
D12-97 0.6 1.2 3 2.7 3 
D12-98 0.6 0.6 3 3.6 3.3 
D12-99 0.6 1.2 3 3.3 3 
D12-100 0.6 1.8 3 3.6 3 
D12-101 0.6 1.8 3 3.6 3.3 
D12-104 0.6 1.2 2.7 2.7 2.4 
D12-106 0.6 1.2 2.1 3 3.3 
D12-107 0.6 0.9 2.7 2.1 1.8 
D12-108 0.6 2.1 3 2.7 3 
D12-109 0.6 2.4 2.4 2.4 2.1 
D12-110 0.6 2.7 3 3 3 
D12-111 0.6 2.4 3 3 3 
D12-112 0.6 1.5 3 2.7 2.7 
D12-113 0.6 2.4 2.4 2.4 2.7 
D12-114 0.6 2.1 2.7 2.7 2.4 
D12-115 0.6 2.4 3.6 3.6 3 
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D12-116 0.6 1.8 3 2.7 2.7 
D12-117 0.6 2.4 3 2.7 2.4 
D12-118 0.6 2.1 3 3 2.4 
D12-119 0.6 2.1 3.3 3.3 2.4 
D12-120 0.6 1.8 3 2.7 3 
D12-121 0.6 2.4 3.3 3.6 3 
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Additional files 
Supplemental Table 1 – RNA Assessment (NanoDrop, Bioanalyzer) 
Hi Pro ng/ul  260/280  Hi No Pro ng/ul  260/280  
D10-100 8-3 193.27 2.15 D10-173 11-15 47.33 2.07 
D10-100 8-4 183.77 2.15 D10-173 11-16 114.97 2.13 
D10-100 8-17 100.58 2.13 D10-173 11-29 96.82 2.14 
D10-100 8-18 35.45 2.05 D10-173 11-30 69.33 2.18 
D10-109 8-3 665.35 2.15 D10-184 11-15 81.29 2.15 
D10-109 8-4 416.97 2.14 D10-184 11-16 125.66 2.12 
D10-109 8-17 87.64 2.16 D10-184 11-29 96.83 2.15 
D10-109 8-18 550.41 2.14 D10-184 11-30 86.27 2.12 
D10-121 8-3 317.19 2.14 D10-186 11-15 63.59 1.99 
D10-121 8-4 357.77 2.15 D10-186 11-16 27.77 2.15 
D10-121 8-17 213.93 2.17 D10-186 11-29 179.2 2.15 
D10-121 8-18 255.03 2.14 D10-186 11-30 60.01 2.16 
D10-132 8-3 329.39 2.13 Lo No Pro 
D10-132 8-4 419.73 2.11 D10-101 8-3 413.59 2.06 
D10-132 8-17 480.74 2.13 D10-101 8-4 342.51 2.11 
D10-132 8-18 319.09 2.15 D10-101 8-17 125.22 2.13 
Ad Null D10-101 8-18 207.13 2.09 
12-97 6/12 244.76 2.07 Sham ng/ul  260/280  
12-97 6/13 124.47 2.02 D10-113 8/17 316.56 2.15 
12-97 6/26 89.82 1.98 D10-113 8/18 351.92 2.14 
12-97 6/27 51.95 1.95 D10-118 8/17 267.88 2.16 
12-98 6/12 264.52 2.04 D10-118 8/18 138.35 2.17 
12-98 6/13 130.03 1.98 D10-131 8/17 324.01 2.16 
12-98 6/26 112.41 2.02 D10-131 8/18 293.5 2.15 
12-98 6/27 86.8 1.98 D10-133 8/17 80.12 2.15 
12-99 6/12 297.47 2.05 D10-133 8/18 266.38 2.17 
12-99 6/13 103.85 1.95 Lo Pro 
12-99 6/26 39.92 1.79 D10-115 8-3 345.94 2.14 
12-99 6/27 27.91 1.52 D10-115 8-4 270.05 2.15 
12-100 6/12 254.07 2.02 D10-115 8-17 85.18 2.17 
12-100 6/13 128.45 1.99 D10-115 8-18 166.04 2.12 
12-100 6/26 44.57 1.82 
12-100 6/27 57.24 1.89 
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Hi Pro 
 
 
 
Hi No Pro 
D10-100 8-3 RIN: 9.10 D10-173 11-15 RIN: 9.40 
D10-100 8-4 RIN: 8.80 D10-173 11-16 RIN: 9.30 
D10-100 8-17 RIN: 9.30 D10-173 11-29 RIN: 9.30 
D10-100 8-18 RIN: 9.30 D10-173 11-30 RIN: 9.60 
D10-109 8-3 RIN: 8.90 D10-184 11-15 RIN: 9.50 
D10-109 8-4 RIN: 9.40 D10-184 11-16 RIN: 8.60 
D10-109 8-17 RIN: 9.60 D10-184 11-29 RIN: 9.30 
D10-109 8-18 RIN: 9.20 D10-184 11-30 RIN: 9.60 
D10-121 8-3 RIN: 8.70 D10-186 11-15 RIN: 8.90 
D10-121 8-4 RIN: 9.50 D10-186 11-16 RIN: 9.20 
D10-121 8-17 RIN: 9.60 D10-186 11-29 RIN: 9.30 
D10-121 8-18 RIN: 9.60 D10-186 11-30 RIN: 9.60 
D10-132 8-3 RIN: 9.70 Lo Pro 
D10-132 8-4 RIN: 9.30 D10-115 8-3 RIN: 9.30 
D10-132 8-17 RIN: 8.90 D10-115 8-4 RIN: 9.70 
D10-132 8-18 RIN: 9.50 D10-115 8-17 RIN: 9.20 
Sham D10-115 8-18 RIN: 9.60 
D10-113  8/17 RIN: 9.10 Lo No Pro 
D10-113  8/18 RIN: 9.30 D10-101 8-3 RIN: 9.30 
D10-118  8/17 RIN: 9.50 D10-101 8-4 RIN: 9.80 
D10-118  8/18 RIN: 9.60 D10-101 8-17 RIN: 8.80 
D10-131  8/17 RIN: 9.60 D10-101 8-18 RIN: 9.50 
D10-131  8/18 RIN: 9.50 
D10-133  8/17 RIN: 8.80 
D10-133  8/18 RIN: 9.70 
  
RNA Integrity Number (RIN) 
ranges from 0 to 10 where 10 is 
greatest integrity 
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Supplemental Table 2 – Cyanine Dye Incorporation 
Sample ID Cy-3 pmol/µl Cy-5 pmol/µl ng/µl  activity 
Hi Pro 
D10-100 8-3 Cy-3 1.08 -0.11 97.86 11.04 
D10-100 8-4 Cy-3 0.81 -0.07 90.2 8.98 
D10-100 8-17 Cy-3 0.63 -0.19 88.52 7.12 
D10-100 8-18 Cy-3 0.62 -0.05 54.81 11.31 
D10-109 8-3 Cy-3 1.39 -0.05 99.66 13.95 
D10-109 8-4 Cy-3 1.11 -0.15 109.15 10.17 
D10-109 8-17 Cy-3 0.84 -0.2 109.46 7.67 
D10-109 8-18 Cy-3 1.02 -0.16 91.96 11.09 
D10-121 8-3 Cy-3 1.64 0.06 109.79 14.94 
D10-121 8-4 Cy-3 0.99 -0.03 73.98 13.38 
D10-121 8-17 Cy-3 1 0.01 71.11 14.06 
D10-121 8-18 Cy-3 1.29 -0.04 96.43 13.38 
D10-132 8-3 Cy-3 1.29 0 89.94 14.34 
D10-132 8-4 Cy-3 0.93 0.02 71.29 13.05 
D10-132 8-17 Cy-3 1.14 -0.07 89.86 12.69 
D10-132 8-18 Cy-3 1.13 -0.13 100.36 11.26 
D10-100 8-3 Cy-5 -0.03 1.5 88.23 17 
D10-100 8-4 Cy-5 -0.27 0.94 75.97 12.37 
D10-100 8-17 Cy-5 -0.2 1.23 95.64 12.86 
D10-100 8-18 Cy-5 0.08 0.78 55.59 14.03 
D10-109 8-3 Cy-5 -0.17 1.47 96.63 15.21 
D10-109 8-4 Cy-5 -0.06 1.4 87.32 16.03 
D10-109 8-17 Cy-5 0.21 1.61 95.9 16.79 
D10-109 8-18 Cy-5 0.13 1.51 96.62 15.63 
D10-121 8-3 Cy-5 -0.13 1.86 124.53 14.94 
D10-121 8-4 Cy-5 -0.06 1.24 81.72 15.17 
D10-121 8-17 Cy-5 0.05 1.49 97.82 15.23 
D10-121 8-18 Cy-5 0.07 1.3 81.32 15.99 
D10-132 8-3 Cy-5 -0.22 1.2 85.72 14 
D10-132 8-4 Cy-5 -0.23 1.21 84.26 14.36 
D10-132 8-17 Cy-5 0 1.19 82.04 14.51 
D10-132 8-18 Cy-5 0.13 1.27 78.37 16.21 
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Hi No Pro 
    
173 11-15 Cy-3 0.91 -0.01 78.99 11.52 
173 11-16 Cy-3 1.2 -0.01 101.79 11.79 
173 11-29 Cy-3 0.84 0 82.34 10.2 
173 11-30 Cy-3 0.86 0.05 78.47 10.96 
184 11-15 Cy-3 1.48 -0.02 117.48 12.6 
184 11-16 Cy-3 1.26 0.08 101.57 12.41 
184 11-29 Cy-3 1.41 0.13 107.64 13.1 
184 11-30 Cy-3 0.92 0.11 76.11 12.09 
186 11-15 Cy-3 0.74 0.04 74.21 9.97 
186 11-16 Cy-3 0.66 0.05 67.51 9.78 
186 11-29 Cy-3 0.92 0.05 86.9 10.59 
186 11-30 Cy-3 0.73 0.11 70.95 10.29 
173 11-15 Cy-5 -0.08 1.23 79.19 15.53 
173 11-16 Cy-5 -0.02 1.24 74.72 16.6 
173 11-29 Cy-5 -0.09 1.3 75.32 17.26 
173 11-30 Cy-5 0.46 1.07 65.07 16.44 
184 11-15 Cy-5 0 1.58 98.93 15.97 
184 11-16 Cy-5 -0.02 1.57 90.6 17.33 
184 11-29 Cy-5 -0.09 1.55 93.72 16.54 
184 11-30 Cy-5 -0.16 1.01 62.5 16.16 
186 11-15 Cy-5 -0.12 1.11 72.37 15.34 
186 11-16 Cy-5 -0.1 0.96 58.02 16.55 
186 11-29 Cy-5 -0.11 1.31 75.28 17.4 
186 11-30 Cy-5 -0.2 0.91 50.96 17.86 
Lo Pro 
D10-115 8-3 Cy-3 1.41 0 100.05 14.09 
D10-115 8-4 Cy-3 1.11 -0.02 93.04 11.93 
D10-115 8-17 Cy-3 1.25 -0.05 98.39 12.7 
D10-115 8-18 Cy-3 1.26 -0.1 97.1 12.98 
D10-115 8-3 Cy-5 -0.51 1.14 99 11.52 
D10-115 8-4 Cy-5 0.08 1.26 76.36 16.5 
D10-115 8-17 Cy-5 0.16 1.46 89.82 16.25 
D10-115 8-18 Cy-5 0.11 1.39 86.49 16.07 
  
 - 59 - 
 
Lo No Pro 
D10-101 8-3 Cy-3 1.29 -0.05 89.04 14.49 
D10-101 8-4 Cy-3 1.11 -0.14 108.14 10.26 
D10-101 8-17 Cy-3 1.25 -0.08 100.06 12.49 
D10-101 8-18 Cy-3 1.07 -0.13 87.47 12.23 
D10-101 8-3 Cy-5 -0.06 1.48 90.43 16.37 
D10-101 8-4 Cy-5 -0.08 1.44 85.77 16.79 
D10-101 8-17 Cy-5 0.23 1.76 104.28 16.88 
D10-101 8-18 Cy-5 0.22 1.67 96.22 17.36 
Sham 
113 8/17 Cy3 0.95 -0.07 83.69 11.35 
113 8/18 Cy3 0.65 -0.33 64.66 10.05 
118 8/17 Cy3 0.9 -0.1 77.93 11.55 
118 8/18 Cy3 1.12 -0.34 96.13 11.65 
131 8/17 Cy3 1.24 -0.08 94.53 13.12 
131 8/18 Cy3 1.02 -0.11 83.9 12.16 
133 8/17 Cy3 0.87 -0.17 97.78 8.9 
133 8/18 Cy3 1.07 -0.09 82.37 12.99 
113 8/17 Cy5 -0.21 1.2 96.95 12.38 
113 8/18 Cy5 0.09 1.25 78.54 15.92 
118 8/17 Cy5 -0.78 0.83 104.49 7.94 
118 8/18 Cy5 0.12 1.2 76.77 15.63 
131 8/17 Cy5 0.13 1.22 76.59 15.93 
131 8/18 Cy5 0.15 1.25 80.54 15.52 
133 8/17 Cy5 -0.34 1.13 100.33 11.26 
133 8/18 Cy5 -0.23 0.97 85 11.41 
  
 - 60 - 
 
Ad Null 
12-97 6/12 Cy3 1.38 0.05 120.45 11.46 
12-97 6/13 Cy3 1.29 -0.08 125.63 10.27 
12-97 6/26 Cy3 1.42 -0.09 126.86 11.19 
12-97 6/27 Cy3 1.26 0 118.3 10.65 
12-98 6/12 Cy3 1.04 -0.03 104.4 9.96 
12-98 6/13 Cy3 1.38 0.05 118.88 11.61 
12-98 6/26 Cy3 1.33 -0.11 130.67 10.18 
12-98 6/27 Cy3 1.44 0.01 133.06 10.82 
12-99 6/12 Cy3 1.05 -0.03 105.75 9.93 
12-99 6/13 Cy3 0.98 -0.01 91.44 10.72 
12-99 6/26 Cy3 1.15 -0.07 110.01 10.45 
12-99 6/27 Cy3 0.97 -0.02 87.87 11.04 
12-100 6/12 Cy3 0.85 -0.05 91.35 9.3 
12-100 6/13 Cy3 1.12 -0.14 116.47 9.62 
12-100 6/26 Cy3 1.22 0.03 107.66 11.33 
12-100 6/27 Cy3 1.17 -0.13 114.41 10.23 
12-97 6/12 Cy5 0.21 2.04 108.74 18.76 
12-97 6/13 Cy5 0.17 2.2 121.29 18.14 
12-97 6/26 Cy5 0.06 2.21 128.19 17.24 
12-97 6/27 Cy5 0.1 2.25 124.89 18.02 
12-98 6/12 Cy5 0.04 1.81 107.08 16.9 
12-98 6/13 Cy5 0.13 1.79 102.95 17.39 
12-98 6/26 Cy5 0.23 2.07 112.99 18.32 
12-98 6/27 Cy5 0.31 2.48 135.87 18.25 
12-99 6/12 Cy5 0.23 1.67 85.09 19.63 
12-99 6/13 Cy5 0.08 1.53 90.53 16.9 
12-99 6/26 Cy5 0.31 2.01 110.63 18.17 
12-99 6/27 Cy5 0.05 1.55 95.57 16.22 
12-100 6/12 Cy5 0.12 1.86 104.94 17.72 
12-100 6/13 Cy5 0.1 1.83 108.38 16.89 
12-100 6/26 Cy5 0.24 1.86 105.79 17.58 
12-100 6/27 Cy5 0.31 2.15 114.41 18.79 
 
 Specific activity is defined as 1,000 multiplied by the 
ratio of dye concentration over cRNA concentration. 
Values ≥ 7 are appropriate for hybridization. 
 
